Veracyte(US:VCYT)2025-07-04 07:21Financial Performance - Veracyte achieved total revenue of $446 million in 2024[19] - The company experienced a 28% growth in testing revenue in 2024[19] - Veracyte reported GAAP Net Income of $24 million in 2024[19] - The Adjusted EBITDA margin for 2024 was 20.6%[19] Product Performance and Market Position - Decipher Prostate is a market leader in molecular diagnostics for prostate cancer prognosis and prediction[23] - Afirma is a market leader in molecular thyroid diagnostics[33] - Decipher experienced 37% volume growth and 33% revenue growth in Q1 2025[23] - Afirma experienced 10% volume growth and 6% revenue growth in Q1 2025[33] Strategic Initiatives - Veracyte is investing in complementary AI-based imaging and molecular analysis[30] - The company plans to launch Prosigna LDT in its CLIA lab, based on its v2 Veracyte transcriptome, with commercial availability expected in mid-2026[40]